Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1771645

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1771645

Traumatic Brain Injury Biomarkers Market Size, Share & Trends Analysis Report By Type (Protein Biomarkers, Genetic Biomarkers), By Sample Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Traumatic Brain Injury Biomarkers Market Summary

The global traumatic brain injury biomarkers market size was estimated at USD 1.04 billion in 2024 and is projected to reach USD 4.73 billion by 2033, growing at a CAGR of 18.84% from 2025 to 2033. The market is facing significant growth driven by rising incidents of traumatic brain injuries, growing demand for rapid and point-of-care diagnostics, and a shift towards personalized medicine and telehealth.

Traumatic brain injury (TBI) remains a major global health concern, ranking among the leading causes of long-term disability and mortality. According to the Centers for Disease Control and Prevention, in 2024, 2.8 million people in America were diagnosed with brain injury every year, and more than 56,000 people died as a result of TBI. Although everyone is at risk of sustaining a traumatic brain injury (TBI), males are approximately 1.5 times more likely than females to experience a TBI and have a mortality rate that is three times higher.

Factors such as increasing road traffic accidents, sports-related injuries, falls among the elderly, and military combat injuries contribute significantly to this trend. Each year, traumatic brain injury (TBI) results in disability for six times more individuals than spinal cord injuries, multiple sclerosis, HIV/AIDS, and breast cancer combined. The pie chart below illustrates leading causes of TBI:

This surge in TBI cases fuels demand for reliable, early diagnostic tools like biomarkers that can aid in timely detection and treatment, ultimately driving market growth.

Individuals aged 65 and above are the most vulnerable to hospitalization and death caused by traumatic brain injury (TBI), with falls being the leading cause. Across all age groups, men experience higher rates of severe TBI compared to women, and they are not only more frequently hospitalized but also face nearly triple the risk of death from TBI.

Thus, there is a growing need for rapid, portable, and point-of-care diagnostic tools for TBI, particularly in pre-hospital environments such as accident scenes, sports fields, and military battlefields. Biomarker-based tests that provide quick and accurate results enable timely clinical decisions, improving patient outcomes and reducing healthcare costs.

Studies are being conducted to investigate whether biomarkers can be used in clinical trials to support the development of new treatments for traumatic brain injury (TBI). These biomarkers could improve the diagnosis and evaluation of TBI severity, facilitating the selection of suitable patients for participation in drug trials. One such study reported by the USFDA, conducted in September 2022, focused on identifying and validating diagnostic biomarkers that accurately detected traumatic brain injury (TBI) and assessed the severity to improve early diagnosis and patient management. The study successfully identified potential biomarkers that demonstrated a strong correlation with TBI presence and severity, laying the groundwork for improved diagnostic tools and enabling more precise patient selection in future clinical trials.

The increasing focus on personalized medicine is driving demand for biomarker-based diagnostics tailored to individual patient profiles and severity of injury. Biomarkers enable clinicians to customize treatment strategies, improving outcomes and reducing adverse effects. Innovations in biomarker identification tests are in development with a focus on personalized medicine.

For instance, in May 2024, bioMerieux received U.S. FDA 510(k) clearance for VIDAS TBI, a serum-based test designed to assist in evaluating patients with mild traumatic brain injury (mTBI), including concussions. This test assists in detecting patients who are unlikely to have acute intracranial lesions (ICL), which helps decrease the number of unnecessary head CT scans. VIDAS TBI also enables healthcare providers to make faster, better-informed decisions tailored to individual patient needs. Thus, inculcating such approaches promotes continuous monitoring and timely intervention, supporting market growth by integrating biomarker testing into personalized therapeutic approaches.

Global Traumatic Brain Injury Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global traumatic brain injury biomarkers market report based on type, sample type, application, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Protein Biomarkers
  • Genetic Biomarkers
  • Metabolomic Biomarkers
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood-based
  • Cerebrospinal fluid (CSF)-based
  • Urine-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnosis
  • Prognosis
  • Monitoring treatment response
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-624-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Sample Type
    • 1.2.3. Application
    • 1.2.4. End use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Sample type outlook
    • 2.2.3. Application outlook
    • 2.2.4. End use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Traumatic Brain Injury Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Traumatic Brain Injury Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Traumatic Brain Injury Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Traumatic Brain Injury Biomarkers Market: Type Movement Analysis
  • 4.4. Traumatic Brain Injury Biomarkers Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.5. Traumatic Brain Injury Biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Protein biomarkers
    • 4.6.1. Protein biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7. Genetic biomarkers
    • 4.7.1. Genetic biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.8. Metabolomic biomarkers
    • 4.8.1. Metabolomic biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Traumatic Brain Injury Biomarkers Market: Sample type Estimates & Trend Analysis

  • 5.1. Sample type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Traumatic Brain Injury Biomarkers Market by Sample type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Blood-based
    • 5.5.1. Blood-based Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Cerebrospinal fluid (CSF)-based
    • 5.6.1. Cerebrospinal fluid (CSF)-based Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Urine-based
    • 5.7.1. Urine-based Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Traumatic Brain Injury Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Traumatic Brain Injury Biomarkers Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Diagnosis
    • 6.5.1. Diagnosis Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Prognosis
    • 6.6.1. Prognosis Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Monitoring treatment response
    • 6.7.1. Monitoring treatment response Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Traumatic Brain Injury Biomarkers Market: End use Estimates & Trend Analysis

  • 7.1. End use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Traumatic Brain Injury Biomarkers Market by End use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospitals & Clinics
    • 7.5.1. Hospitals & Clinics Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Diagnostic Laboratories
    • 7.6.1. Diagnostic Laboratories Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Research Institutes
    • 7.7.1. Research Institutes Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Traumatic Brain Injury Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/Reimbursement
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/Reimbursement
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/Reimbursement
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/Reimbursement
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/Reimbursement
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/Reimbursement
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
      • 9.3.3.1. Quanterix.
        • 9.3.3.1.1. Company overview
        • 9.3.3.1.2. Financial performance
        • 9.3.3.1.3. Services benchmarking
        • 9.3.3.1.4. Strategic initiatives
      • 9.3.3.2. Banyan Biomarkers, Inc.
        • 9.3.3.2.1. Company overview
        • 9.3.3.2.2. Financial performance
        • 9.3.3.2.3. Services benchmarking
        • 9.3.3.2.4. Strategic initiatives
      • 9.3.3.3. Abbott
        • 9.3.3.3.1. Company overview
        • 9.3.3.3.2. Financial performance
        • 9.3.3.3.3. Services benchmarking
        • 9.3.3.3.4. Strategic initiatives
      • 9.3.3.4. Siemens Healthineers AG
        • 9.3.3.4.1. Company overview
        • 9.3.3.4.2. Financial performance
        • 9.3.3.4.3. Services benchmarking
        • 9.3.3.4.4. Strategic initiatives
      • 9.3.3.5. GE Healthcare.
        • 9.3.3.5.1. Company overview
        • 9.3.3.5.2. Financial performance
        • 9.3.3.5.3. Services benchmarking
        • 9.3.3.5.4. Strategic initiatives
      • 9.3.3.6. Koninklijke Philips N.V.
        • 9.3.3.6.1. Company overview
        • 9.3.3.6.2. Financial performance
        • 9.3.3.6.3. Services benchmarking
        • 9.3.3.6.4. Strategic initiatives
      • 9.3.3.7. Fujirebio
        • 9.3.3.7.1. Company overview
        • 9.3.3.7.2. Financial performance
        • 9.3.3.7.3. Services benchmarking
        • 9.3.3.7.4. Strategic initiatives
      • 9.3.3.8. Thermo Fisher Scientific Inc.
        • 9.3.3.8.1. Company overview
        • 9.3.3.8.2. Financial performance
        • 9.3.3.8.3. Services benchmarking
        • 9.3.3.8.4. Strategic initiatives
      • 9.3.3.9. Randox Laboratories Ltd.
        • 9.3.3.9.1. Company overview
        • 9.3.3.9.2. Financial performance
        • 9.3.3.9.3. Services benchmarking
        • 9.3.3.9.4. Strategic initiatives
      • 9.3.3.10. Immunarray.
        • 9.3.3.10.1. Company overview
        • 9.3.3.10.2. Financial performance
        • 9.3.3.10.3. Services benchmarking
        • 9.3.3.10.4. Strategic initiatives
      • 9.3.3.11. Oculogica
        • 9.3.3.11.1. Company overview
        • 9.3.3.11.2. Financial performance
        • 9.3.3.11.3. Services benchmarking
        • 9.3.3.11.4. Strategic initiatives
      • 9.3.3.12. NeuroTrauma Sciences, LLC
        • 9.3.3.12.1. Company overview
        • 9.3.3.12.2. Financial performance
        • 9.3.3.12.3. Services benchmarking
        • 9.3.3.12.4. Strategic initiatives
      • 9.3.3.13. BRAINBox Solutions, Inc.
        • 9.3.3.13.1. Company overview
        • 9.3.3.13.2. Financial performance
        • 9.3.3.13.3. Services benchmarking
        • 9.3.3.13.4. Strategic initiatives
      • 9.3.3.14. BioMerieux
        • 9.3.3.14.1. Company overview
        • 9.3.3.14.2. Financial performance
        • 9.3.3.14.3. Services benchmarking
        • 9.3.3.14.4. Strategic initiatives
      • 9.3.3.15. Myriad Genetics, Inc.
        • 9.3.3.15.1. Company overview
        • 9.3.3.15.2. Financial performance
        • 9.3.3.15.3. Services benchmarking
        • 9.3.3.15.4. Strategic initiatives
      • 9.3.3.16. QIAGEN N.V.
        • 9.3.3.16.1. Company overview
        • 9.3.3.16.2. Financial performance
        • 9.3.3.16.3. Services benchmarking
        • 9.3.3.16.4. Strategic initiatives
      • 9.3.3.17. F. Hoffmann-La Roche Ltd
        • 9.3.3.17.1. Company overview
        • 9.3.3.17.2. Financial performance
        • 9.3.3.17.3. Services benchmarking
        • 9.3.3.17.4. Strategic initiatives
      • 9.3.3.18. Abcam Limited
        • 9.3.3.18.1. Company overview
        • 9.3.3.18.2. Financial performance
        • 9.3.3.18.3. Services benchmarking
        • 9.3.3.18.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-624-1

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Traumatic Brain Injury biomarkers market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 4 North America Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 5 North America Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 9 U.S Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 10 U.S Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 13 Canada Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 14 Canada Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 16 Mexico Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 17 Mexico Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 18 Mexico Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 20 Europe Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 21 Europe Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 23 UK Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 25 UK Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 26 UK Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Germany Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 28 Germany Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 29 Germany Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 30 Germany Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 31 France Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 32 France Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 33 France Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 34 France Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Italy Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 36 Italy Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 37 Italy Traumatic Brain Injury biomarkers market, application, 2021 - 2033 (USD Million)
  • Table 38 Italy Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Spain Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 40 Spain Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 41 Spain Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 42 Spain Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Denmark Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 44 Denmark Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 45 Denmark Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 46 Denmark Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Sweden Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 48 Sweden Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 49 Sweden Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 50 Sweden Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Norway Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 52 Norway Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 53 Norway Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 54 Norway Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 55 Asia Pacific Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Japan Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 60 Japan Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 61 Japan Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 62 Japan Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 63 China Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 64 China Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 65 China Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 66 China Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 67 India Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 68 India Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 69 India Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 70 India Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Australia Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 72 Australia Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 73 Australia Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 74 Australia Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 75 South Korea Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 76 South Korea Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 77 South Korea Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 78 South Korea Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Thailand Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 80 Thailand Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 81 Thailand Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 82 Thailand Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Latin America Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 84 Latin America Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 85 Latin America Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 86 Latin America Traumatic Brain Injury biomarkers market, by end use 2021 - 2033 (USD Million)
  • Table 87 Brazil Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 88 Brazil Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 89 Brazil Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 90 Brazil Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Argentina Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 92 Argentina Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 93 Argentina Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 94 Argentina Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 95 MEA Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 96 MEA Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 97 MEA Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 98 MEA Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 99 South Africa Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 100 South Africa Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 101 South Africa Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 102 South Africa Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 103 Saudi Arabia Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 104 Saudi Arabia Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 105 Saudi Arabia Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 106 Saudi Arabia Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 107 UAE Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 108 UAE Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 109 UAE Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 110 UAE Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 111 Kuwait Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 112 Kuwait Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 113 Kuwait Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 114 Kuwait Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Traumatic Brain Injury biomarkers market: market outlook
  • Fig. 14 Traumatic Brain Injury biomarkers competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Traumatic Brain Injury Biomarkers market driver impact
  • Fig. 20 Traumatic Brain Injury Biomarkers market restraint impact
  • Fig. 21 Traumatic Brain Injury Biomarkers market strategic initiatives analysis
  • Fig. 22 Traumatic Brain Injury Biomarkers market: Type movement analysis
  • Fig. 23 Traumatic Brain Injury Biomarkers market: Type outlook and key takeaways
  • Fig. 24 Protein biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 25 Genetic biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 26 Metabolomic biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 27 Traumatic Brain Injury Biomarkers Market: Sample type movement analysis
  • Fig. 28 Traumatic Brain Injury Biomarkers market: Sample type outlook and key takeaways
  • Fig. 29 Blood-based market estimates and forecasts, 2021 - 2033
  • Fig. 30 Cerebrospinal fluid (CSF)-based market estimates and forecasts, 2021 - 2033
  • Fig. 31 Urine-based market estimates and forecasts, 2021 - 2033
  • Fig. 32 Traumatic Brain Injury Biomarkers Market: Application movement analysis
  • Fig. 33 Traumatic Brain Injury Biomarkers market: Application outlook and key takeaways
  • Fig. 34 Diagnosis market estimates and forecasts, 2021 - 2033
  • Fig. 35 Prognosis market estimates and forecasts, 2021 - 2033
  • Fig. 36 Monitoring treatment response market estimates and forecasts, 2021 - 2033
  • Fig. 37 Traumatic Brain Injury Biomarkers Market: End use movement analysis
  • Fig. 38 Traumatic Brain Injury Biomarkers market: End use outlook and key takeaways
  • Fig. 39 Hospitals & Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 40 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 41 Research Institutes market estimates and forecasts, 2021 - 2033
  • Fig. 42 Global Traumatic Brain Injury Biomarkers market: Regional movement analysis
  • Fig. 43 Global Traumatic Brain Injury Biomarkers market: Regional outlook and key takeaways
  • Fig. 44 Global Traumatic Brain Injury Biomarkers market share and leading players
  • Fig. 45 North America market share and leading players
  • Fig. 46 Europe market share and leading players
  • Fig. 47 Asia Pacific market share and leading players
  • Fig. 48 Latin America market share and leading players
  • Fig. 49 Middle East & Africa market share and leading players
  • Fig. 50 North America
  • Fig. 51 North America market estimates and forecasts, 2021 - 2033
  • Fig. 52 U S
  • Fig. 53 U S market estimates and forecasts, 2021 - 2033
  • Fig. 54 Canada
  • Fig. 55 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 56 Mexico
  • Fig. 57 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 58 Europe
  • Fig. 59 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 60 UK
  • Fig. 61 UK market estimates and forecasts, 2021 - 2033
  • Fig. 62 Germany
  • Fig. 63 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 64 France
  • Fig. 65 France market estimates and forecasts, 2021 - 2033
  • Fig. 66 Italy
  • Fig. 67 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 68 Spain
  • Fig. 69 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 70 Denmark
  • Fig. 71 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 72 Sweden
  • Fig. 73 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 74 Norway
  • Fig. 75 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 76 Asia Pacific
  • Fig. 77 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 78 China
  • Fig. 79 China market estimates and forecasts, 2021 - 2033
  • Fig. 80 Japan
  • Fig. 81 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 82 India
  • Fig. 83 India market estimates and forecasts, 2021 - 2033
  • Fig. 84 Thailand
  • Fig. 85 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 86 South Korea
  • Fig. 87 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 88 Australia
  • Fig. 89 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 90 Latin America
  • Fig. 91 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 92 Brazil
  • Fig. 93 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 94 Argentina
  • Fig. 95 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 96 Middle East and Africa
  • Fig. 97 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 98 South Africa
  • Fig. 99 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 100 Saudi Arabia
  • Fig. 101 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 102 UAE
  • Fig. 103 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 104 Kuwait
  • Fig. 105 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 106 Market share of key market players- Traumatic Brain Injury Biomarkers market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!